Dandan Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dandan Tian has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Qing Ye
Zhejiang University School of Medicine
4 shared publications Jianming Zhou
Department of Clinical Laboratory, National Clinical Research Center for Child Health, National Children's Regional Medical Center, the Children's Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publicationsWenjian Nie
Department of Clinical Laboratory, National Clinical Research Center for Child Health, National Children's Regional Medical Center, the Children's Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publications- Yanhong Sun
National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Children’s Hospital, Zhejiang University School of Medicine Department of Clinical Laboratory Hangzhou 310052
2 shared publications - Allan E. Rettie
University of Washington
1 shared publication - Jian Zhang
Department of Orthopedics, Wuxi No. 2 People’s Hospital, Affiliated Wuxi Clinical College of Nantong University
1 shared publication
Latest Publications
- 22 January 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (1) , e29412
Study on the epidemiological characteristics of enterovirus among pediatric patients in Hangzhou, China: A comparison between the pre‐COVID‐19, COVID‐19 pandemic, and post‐COVID‐19 periods
Nonpharmaceutical interventions (NPIs) for coronavirus disease 2019 (COVID‐19) not only reduce the prevalence of this disease among children but also influence the transmission of other viruses. This retrospective study investigated the impact of NPIs on human enterovirus (HEV) infection in children diagnosed with hand, foot, and mouth disease (HFMD) or herpangina (HA) in Hangzhou, China. We collected and analyzed the laboratory results and clinical data of children diagnosed with HFMD or HA during the following periods: pre‐COVID‐19 (January 2019 to December 2019), the COVID‐19 pandemic (January 2020 to December 2022), and post‐COVID‐19 (January to December 2023). A total of 41 742 specimens that met the inclusion criteria were obtained, of which 1998 (4.79%) tested positive for enterovirus. In comparison to those in the pre‐COVID‐19 period, which had 695 (5.63%) HEV‐positive specimens, the numbers dramatically decreased to 69 (1.19%), 398 (5.12%), and 112 (1.58%) in 2020, 2021, and 2022, respectively, but significantly increased to 724 (8.27%) in 2023. Seasonal peaks of infections occurred in May, June, July, and August each year, with the total detection rate ranging from 2019 to 2023 being 9.41% in May, 22.47% in June, 28.23% in July, and 12.16% in August, respectively. The difference in the detection rates of HEV infection between males and females was statistically significant (p < 0.005), with 5.11% (1221/23 898) of males and 4.35% (777/17 844) of females testing positive, resulting in a male‐to‐female positive ratio of 1.57:1. Among the age groups, 11.25% (378/3360) of the children aged 3–5 years had the highest detection rate, which steadily decreased with increasing or decreasing age. The detection of HEV indicated that >95% of the viruses were other types than the previously commonly reported enterovirus 71 (EV‐A71) and coxsackievirus A16 (CV‐A16). In conclusion, NPIs for COVID‐19 may be effective at reducing the transmission of HEV. However, with the relaxation of NPIs, the detection rate of HEVs increased slowly to a certain extent. Active awareness and surveillance of the epidemiological characteristics of HEV are essential for preventing, controlling, and managing the development of HFMD and HA, as well as contributing to the development of a multivalent HFMD vaccine.
- 22 January 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (1) , e29412
Study on the epidemiological characteristics of enterovirus among pediatric patients in Hangzhou, China: A comparison between the pre‐COVID‐19, COVID‐19 pandemic, and post‐COVID‐19 periods
Nonpharmaceutical interventions (NPIs) for coronavirus disease 2019 (COVID‐19) not only reduce the prevalence of this disease among children but also influence the transmission of other viruses. This retrospective study investigated the impact of NPIs on human enterovirus (HEV) infection in children diagnosed with hand, foot, and mouth disease (HFMD) or herpangina (HA) in Hangzhou, China. We collected and analyzed the laboratory results and clinical data of children diagnosed with HFMD or HA during the following periods: pre‐COVID‐19 (January 2019 to December 2019), the COVID‐19 pandemic (January 2020 to December 2022), and post‐COVID‐19 (January to December 2023). A total of 41 742 specimens that met the inclusion criteria were obtained, of which 1998 (4.79%) tested positive for enterovirus. In comparison to those in the pre‐COVID‐19 period, which had 695 (5.63%) HEV‐positive specimens, the numbers dramatically decreased to 69 (1.19%), 398 (5.12%), and 112 (1.58%) in 2020, 2021, and 2022, respectively, but significantly increased to 724 (8.27%) in 2023. Seasonal peaks of infections occurred in May, June, July, and August each year, with the total detection rate ranging from 2019 to 2023 being 9.41% in May, 22.47% in June, 28.23% in July, and 12.16% in August, respectively. The difference in the detection rates of HEV infection between males and females was statistically significant (p < 0.005), with 5.11% (1221/23 898) of males and 4.35% (777/17 844) of females testing positive, resulting in a male‐to‐female positive ratio of 1.57:1. Among the age groups, 11.25% (378/3360) of the children aged 3–5 years had the highest detection rate, which steadily decreased with increasing or decreasing age. The detection of HEV indicated that >95% of the viruses were other types than the previously commonly reported enterovirus 71 (EV‐A71) and coxsackievirus A16 (CV‐A16). In conclusion, NPIs for COVID‐19 may be effective at reducing the transmission of HEV. However, with the relaxation of NPIs, the detection rate of HEVs increased slowly to a certain extent. Active awareness and surveillance of the epidemiological characteristics of HEV are essential for preventing, controlling, and managing the development of HFMD and HA, as well as contributing to the development of a multivalent HFMD vaccine.
- Open Access
- 28 August 2023
- Published by Wiley
Study on the Epidemiological Characteristics of Common Enterovirus among Pediatric Patients in Hangzhou, China: A Comparison between the Pre-COVID-19, COVID-19 Pandemic, and Post-COVID-19 Periods
Nonpharmaceutical interventions (NPIs) against coronavirus disease 2019 (COVID-19) reduced the prevalence of coronavirus among children and influenced the transmission of other viruses. This study investigates the impact of NPIs on human enterovirus (HEV) among children in Hangzhou, China. We collected and analyzed the laboratory results and clinical data of children diagnosed with hand, foot, and mouth disease (HFMD) or herpangina (HA) during the following periods: pre-COVID-19 (January 2019 to December 2019), COVID-19 pandemic (January 2020 to December 2022), and post-COVID-19 (January to August 2023). A total of 38,582 specimens that met the inclusion criteria were enrolled, of which 1,777 (5.58%) tested positive for enterovirus. In comparison to the pre-COVID-19 period, which had 695 (5.63%) HEV-positive specimens, the numbers dramatically decreased to 69 (1.19%), 398 (5.12%), and 112 (1.58%) in 2020, 2021, and 2022, respectively, but significantly increased to 503 (9.00%) in 2023. Seasonal peaks of infections occurred between May and August each year, with positive rates of 10.58%, 25.27%, 31.74%, and 10.97%, respectively. Notably, June and July accounted for half of all cases, with a rate of 57.01%. The difference in the positive rates of HEV infection between males and females was statistically significant (P<0.005), with 5.12% (1,084/21,176) and 4.43% (693/15,629) testing positive, respectively, resulting in a male to female ratio of 1.56:1. Among the same age groups, children aged 3-5 years and 5-7 years had the highest positive rates at 11.03% (342/3,102) and 10.03% (205/2,024), respectively, after synthesizing five years of data. The detection rate of HEV-positive cases increased with age, but after the age of 7, the rate declined. The detected types of HEV indicated that enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16) are no longer the two common pathogens causing HFMD and HA. In conclusion, NPIs for COVID-19 are highly effective in reducing the transmission of HEV. However, the relaxation of NPIs results in a resurgence of HEVs, surpassing prepandemic levels. Active awareness and surveillance of the epidemiological characteristics of HEV are essential for preventing, controlling, and managing the development of HFMD and HA, as well as contributing to the development of a multivalent HFMD vaccine.
- 28 August 2023
- Published by Wiley
Open AccessStudy on the Epidemiological Characteristics of Common Enterovirus among Pediatric Patients in Hangzhou, China: A Comparison between the Pre-COVID-19, COVID-19 Pandemic, and Post-COVID-19 Periods
Nonpharmaceutical interventions (NPIs) against coronavirus disease 2019 (COVID-19) reduced the prevalence of coronavirus among children and influenced the transmission of other viruses. This study investigates the impact of NPIs on human enterovirus (HEV) among children in Hangzhou, China. We collected and analyzed the laboratory results and clinical data of children diagnosed with hand, foot, and mouth disease (HFMD) or herpangina (HA) during the following periods: pre-COVID-19 (January 2019 to December 2019), COVID-19 pandemic (January 2020 to December 2022), and post-COVID-19 (January to August 2023). A total of 38,582 specimens that met the inclusion criteria were enrolled, of which 1,777 (5.58%) tested positive for enterovirus. In comparison to the pre-COVID-19 period, which had 695 (5.63%) HEV-positive specimens, the numbers dramatically decreased to 69 (1.19%), 398 (5.12%), and 112 (1.58%) in 2020, 2021, and 2022, respectively, but significantly increased to 503 (9.00%) in 2023. Seasonal peaks of infections occurred between May and August each year, with positive rates of 10.58%, 25.27%, 31.74%, and 10.97%, respectively. Notably, June and July accounted for half of all cases, with a rate of 57.01%. The difference in the positive rates of HEV infection between males and females was statistically significant (P<0.005), with 5.12% (1,084/21,176) and 4.43% (693/15,629) testing positive, respectively, resulting in a male to female ratio of 1.56:1. Among the same age groups, children aged 3-5 years and 5-7 years had the highest positive rates at 11.03% (342/3,102) and 10.03% (205/2,024), respectively, after synthesizing five years of data. The detection rate of HEV-positive cases increased with age, but after the age of 7, the rate declined. The detected types of HEV indicated that enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16) are no longer the two common pathogens causing HFMD and HA. In conclusion, NPIs for COVID-19 are highly effective in reducing the transmission of HEV. However, the relaxation of NPIs results in a resurgence of HEVs, surpassing prepandemic levels. Active awareness and surveillance of the epidemiological characteristics of HEV are essential for preventing, controlling, and managing the development of HFMD and HA, as well as contributing to the development of a multivalent HFMD vaccine.
- Open Access
- 13 October 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 847-857
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape
During the COVID‐19 pandemic, genetic variants of SARS‐CoV‐2 have been emerging and spreading around the world. Several SARS‐CoV‐2 endemic variants were found in United Kingdom, South Africa, Japan, and India between 2020 and April 2021. Studies have shown that many SARS‐CoV‐2 variants are more infectious than early wild strain and produce immune escape. These SARS‐CoV‐2 variants have brought new challenges to the prevention and control of COVID‐19. This review summarizes and analyzes the biological characteristics of different amino acid mutations and the epidemic characteristics and immune escape of different SARS‐CoV‐2 variants. We hope to provide scientific reference for the monitoring, prevention, and control measures of new SARS‐CoV‐2 variants and the development strategy of the second‐generation vaccine.
- 13 October 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 847-857
Open AccessThe global epidemic of SARS‐CoV‐2 variants and their mutational immune escape
During the COVID‐19 pandemic, genetic variants of SARS‐CoV‐2 have been emerging and spreading around the world. Several SARS‐CoV‐2 endemic variants were found in United Kingdom, South Africa, Japan, and India between 2020 and April 2021. Studies have shown that many SARS‐CoV‐2 variants are more infectious than early wild strain and produce immune escape. These SARS‐CoV‐2 variants have brought new challenges to the prevention and control of COVID‐19. This review summarizes and analyzes the biological characteristics of different amino acid mutations and the epidemic characteristics and immune escape of different SARS‐CoV‐2 variants. We hope to provide scientific reference for the monitoring, prevention, and control measures of new SARS‐CoV‐2 variants and the development strategy of the second‐generation vaccine.
- 1 July 2021
- Published by Elsevier in Autoimmunity Reviews
- Vol. 20 (7) , 102843
Field synopsis and systematic meta-analyses of genetic association studies in neuromyelitis optica
- 1 July 2021
- Published by Elsevier in Autoimmunity Reviews
- Vol. 20 (7) , 102843
Field synopsis and systematic meta-analyses of genetic association studies in neuromyelitis optica
- 21 May 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10) , 1818-1824
Hepatic complications of COVID‐19 and its treatment
Coronavirus disease 2019 (COVID‐19) is highly contagious and has a variety of clinical manifestations, it can affect a number of other organs in addition to the lungs, and liver injury may occur. Severe acute respiratory syndrome coronavirus 2 can cause liver injury through systemic inflammatory response syndrome, cytokine storms, ischemia‐reperfusion injury, side effects of treatment drugs, and underlying liver disease and can attack liver cells directly via angiotensin‐converting enzyme 2. Clinical studies have found that liver injury in COVID‐19 patients mainly manifests as abnormal liver biochemical indicators, but there have been no reports of liver failure caused by this disease. The number of COVID‐19 patients with liver injury is increasing, and the incidence of liver injury in COVID‐19 patients with severe disease are higher than in patients with mild disease. Liver injury may be a risk factor, which worsens in patients with COVID‐19, and hence it is necessary to pay attention to the occurrence of liver injury in the diagnosis and treatment of COVID‐19.
- 21 May 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10) , 1818-1824
Hepatic complications of COVID‐19 and its treatment
Coronavirus disease 2019 (COVID‐19) is highly contagious and has a variety of clinical manifestations, it can affect a number of other organs in addition to the lungs, and liver injury may occur. Severe acute respiratory syndrome coronavirus 2 can cause liver injury through systemic inflammatory response syndrome, cytokine storms, ischemia‐reperfusion injury, side effects of treatment drugs, and underlying liver disease and can attack liver cells directly via angiotensin‐converting enzyme 2. Clinical studies have found that liver injury in COVID‐19 patients mainly manifests as abnormal liver biochemical indicators, but there have been no reports of liver failure caused by this disease. The number of COVID‐19 patients with liver injury is increasing, and the incidence of liver injury in COVID‐19 patients with severe disease are higher than in patients with mild disease. Liver injury may be a risk factor, which worsens in patients with COVID‐19, and hence it is necessary to pay attention to the occurrence of liver injury in the diagnosis and treatment of COVID‐19.
- Open Access
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 814.14
Determining Mechanisms Underlying the Goldenseal‐Midazolam Interaction in Humans Using an In Vitro to In Vivo Extrapolation Approach
Background: ldenseal is a botanical natural product commonly used to self‐treat the common cold and various digestive ailments. Major constituents of goldenseal include the alkaloids berberine, (−)‐hydrastine, and hydrastinine; each constituent contains a methylenedioxyphenyl ring. This structural feature can give rise to time‐dependent inhibition (TDI) of cytochromes P450 (CYPs), which may contribute to the mechanism(s) underlying reported clinical goldenseal‐drug interactions involving the CYP3A probe substrate midazolam. The aims of this work were to 1) determine the TDI kinetics of each constituent towards CYP3A activity (midazolam 1’‐hydroxylation) using human liver and intestinal microsomes (HLM, HIM), 2) apply the kinetic parameters to a mechanistic static model to predict the change in systemic exposure to oral midazolam, and 3) assess the accuracy of the prediction in healthy volunteers. Methods: IC 50 shift experiments were conducted to identify potential time‐dependent inhibitors. K I and k inact were determined using a 6 x 6 matrix of inhibitor concentrations (0.5–90 μM) and primary incubation times (0–20 min). These parameters were applied to a mechanistic static model to predict the change in midazolam area under the plasma concentration‐time curve (AUC). The pharmacokinetics of midazolam and hydroxylated metabolites were determined for 6 healthy volunteers administered a single oral dose of midazolam (2.5 mg) with a well‐characterized goldenseal product (3 g). Results: Only berberine and (−)‐hydrastine showed TDI of CYP3A activity in HLM (K I , 13–42 μM; k inact , 0.015–0.061 min −1 ) and HIM (K I , 5.4–8.5 μM; k inact , 0.040 min −1 ). Berberine additionally showed activation of CYP3A activity (up to 2‐fold compared to vehicle) at low midazolam concentrations (≤5 μM). The increase in the 1’‐ to 4‐hydroxymidazolam (1’‐OH/4‐OH) ratio with increasing berberine concentrations in both HLM and HIM (~6 to ~30) further supported activation of CYP3A activity by berberine. Berberine and (−)‐hydrastine were predicted to increase midazolam AUC by at least 6‐fold. Goldenseal increased midazolam AUC in all of the participants (1.3 to 2.2‐fold). Analysis of 1’‐OH/4‐OH partial AUC ratios did not indicate activation of CYP3A in vivo. Conclusions: The average k inact /K I ratios for berberine (1.3 mL•min −1 •μmol −1 ) and (−)‐hydrastine (4.0 mL•min −1 •μmol −1 ) were near those reported for the clinically relevant time‐dependent CYP3A inhibitors diltiazem and erythromycin (1.8–4.0 mL•min −1 •μmol −1 ), suggesting berberine and (−)‐hydrastine as candidate precipitants of the goldenseal‐midazolam interaction. Activation of CYP3A activity by berberine in vitro may have contributed to the over‐predicted midazolam AUC ratio by the static model, which only considers inhibition. Given that the half‐life for CYP3A4 is ~1–3 days, TDI of CYP3A activity in vivo by goldenseal could have persistent effects beyond cessation of consuming the natural product. Support or Funding Information National Center for Complementary and Integrative Health (U54AT008909) This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 814.14
Open AccessDetermining Mechanisms Underlying the Goldenseal‐Midazolam Interaction in Humans Using an In Vitro to In Vivo Extrapolation Approach
Background: ldenseal is a botanical natural product commonly used to self‐treat the common cold and various digestive ailments. Major constituents of goldenseal include the alkaloids berberine, (−)‐hydrastine, and hydrastinine; each constituent contains a methylenedioxyphenyl ring. This structural feature can give rise to time‐dependent inhibition (TDI) of cytochromes P450 (CYPs), which may contribute to the mechanism(s) underlying reported clinical goldenseal‐drug interactions involving the CYP3A probe substrate midazolam. The aims of this work were to 1) determine the TDI kinetics of each constituent towards CYP3A activity (midazolam 1’‐hydroxylation) using human liver and intestinal microsomes (HLM, HIM), 2) apply the kinetic parameters to a mechanistic static model to predict the change in systemic exposure to oral midazolam, and 3) assess the accuracy of the prediction in healthy volunteers. Methods: IC 50 shift experiments were conducted to identify potential time‐dependent inhibitors. K I and k inact were determined using a 6 x 6 matrix of inhibitor concentrations (0.5–90 μM) and primary incubation times (0–20 min). These parameters were applied to a mechanistic static model to predict the change in midazolam area under the plasma concentration‐time curve (AUC). The pharmacokinetics of midazolam and hydroxylated metabolites were determined for 6 healthy volunteers administered a single oral dose of midazolam (2.5 mg) with a well‐characterized goldenseal product (3 g). Results: Only berberine and (−)‐hydrastine showed TDI of CYP3A activity in HLM (K I , 13–42 μM; k inact , 0.015–0.061 min −1 ) and HIM (K I , 5.4–8.5 μM; k inact , 0.040 min −1 ). Berberine additionally showed activation of CYP3A activity (up to 2‐fold compared to vehicle) at low midazolam concentrations (≤5 μM). The increase in the 1’‐ to 4‐hydroxymidazolam (1’‐OH/4‐OH) ratio with increasing berberine concentrations in both HLM and HIM (~6 to ~30) further supported activation of CYP3A activity by berberine. Berberine and (−)‐hydrastine were predicted to increase midazolam AUC by at least 6‐fold. Goldenseal increased midazolam AUC in all of the participants (1.3 to 2.2‐fold). Analysis of 1’‐OH/4‐OH partial AUC ratios did not indicate activation of CYP3A in vivo. Conclusions: The average k inact /K I ratios for berberine (1.3 mL•min −1 •μmol −1 ) and (−)‐hydrastine (4.0 mL•min −1 •μmol −1 ) were near those reported for the clinically relevant time‐dependent CYP3A inhibitors diltiazem and erythromycin (1.8–4.0 mL•min −1 •μmol −1 ), suggesting berberine and (−)‐hydrastine as candidate precipitants of the goldenseal‐midazolam interaction. Activation of CYP3A activity by berberine in vitro may have contributed to the over‐predicted midazolam AUC ratio by the static model, which only considers inhibition. Given that the half‐life for CYP3A4 is ~1–3 days, TDI of CYP3A activity in vivo by goldenseal could have persistent effects beyond cessation of consuming the natural product. Support or Funding Information National Center for Complementary and Integrative Health (U54AT008909) This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .